Shanghai Shyndec Pharmaceutical Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shanghai Shyndec Pharmaceutical Co Ltd with three other
companies in this sector in China:
Livzon Pharmaceutical Group Incorporated
sales of 8.53 billion Chinese Renmimbi [US$1.35 billion]
of which 43%
was Western Medicine),
Dong-E-E-Jiao Co Ltd
(7.37 billion Chinese Renmimbi [US$1.17 billion]
of which 87%
was Medicine Manufacturing), and
North China Pharmaceutical, Limited
(7.71 billion Chinese Renmimbi [US$1.22 billion]
of which 50%
was Chemical Preparation Medicine).
During the year ended December of 2017, sales at
Shanghai Shyndec Pharmaceutical Co Ltd were 8.52 billion Chinese Renmimbi (US$1.35 billion).
decrease of 6.7%
versus 2016, when the company's sales were 9.12 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 25.1% decline
in Raw Material, from 4.13 billion Chinese Renmimbi to 3.09 billion Chinese Renmimbi.
However, these declines were partially offset by the increase in sales of
Drug Products (up 14.2% to 5.14 billion Chinese Renmimbi)
Health Industry (up 23.6% to 31.34 million Chinese Renmimbi)